Sumitomo Pharma Co (STU:DPM) Moat Score: 5/10 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:DPM Sumitomo Pharma Co Ltd STU:DPM
71 GF Score
Price €6.46
GF Value €4.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co Moat Score?

Sumitomo Pharma Co STU:DPM -5.07% 71 Moat Score is 5 as of Jul. 30, 2026. GuruFocus rates STU:DPM with a GF Score™ of 71/100 and a GF Value™ of €4.66 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Sumitomo Pharma Co ranks better than 94.66% on this metric.

Sumitomo Pharma Co has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Sumitomo Pharma Co has Narrow Moat: Sumitomo Pharma Co Ltd benefits from a solid narrow moat with its strong R&D capabilities and valuable patents. However, intense competition in the pharmaceutical industry limits its pricing power and market share.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sumitomo Pharma Co might have Narrow Moat - Solid narrow moat.

Sumitomo Pharma Co  (STU:DPM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sumitomo Pharma Co Moat Score Related Terms

STU:DPM vs ZTS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sumitomo Pharma Co Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Moat Score falls into.


STU:DPM
71GF Score
Sumitomo Pharma Co Ltd STU:DPM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Sumitomo Pharma Co (STU:DPM) has a Moat Score of 5 as of Jul. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sumitomo Pharma Co ranks #55 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Sumitomo Pharma Co's Moat Score too high?
Sumitomo Pharma Co's current Moat Score is 5. Based on the distribution chart, Sumitomo Pharma Co ranks #55 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sumitomo Pharma Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Moat Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #55 out of 1029 companies for Moat Score. This places Sumitomo Pharma Co in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Sumitomo Pharma Co's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (STU:DPM) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.66, compared to a current price of €6.46 — trading 38.6% above its estimated fair value. The current Moat Score is 5. Sumitomo Pharma Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sumitomo Pharma Co (STU:DPM), the current Moat Score is 5 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (STU:DPM) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of €6.46 is trading 38.6% above its estimated GF Value™ of €4.66. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for STU:DPM:

  • Moat Score: 5
  • GF Value™: €4.66 vs. price of €6.46 (38.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the STU:DPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
71GF Score

Get the complete analysis for STU:DPM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.46
Price
€4.66
GF Value